<生产厂家价格>

3-氨基吡唑

3-氨基吡唑用途

【用途一】
用于制备农药
【用途二】
制备农药。

3-氨基吡唑名称

[ CAS 号 ]:
1820-80-0

[ 中文名 ]:
3-氨基吡唑

[ 英文名 ]:
3-Aminopyrazole

[中文别名 ]:

[英文别名 ]:

3-Pyrazolamine
5-Pyrazolamine
1H-pyrazol-3-ylamine
EINECS 217-338-1
5-AMINOPYRAZOLE
3-amino-pyrazole
3-AMINOPYROZOLE
1H-Pyrazol-5-amine
3-Amino-pyrazol
3-Aminopyarazole

3-氨基吡唑物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
334.5±15.0 °C at 760 mmHg

[ 熔点 ]:
34-37 °C(lit.)

[ 分子式 ]:
C₃H₅N₃

[ 分子量 ]:
83.092

[ 闪点 ]:
182.6±7.6 °C

[ 精确质量 ]:
83.048347

[ PSA ]:
54.70000

[ LogP ]:
-0.29

[ 外观性状 ]:
褐色至淡黄色液体或固体

[ 蒸汽压 ]:
0.0±0.7 mmHg at 25°C

[ 折射率 ]:
1.648

[ 储存条件 ]:
2-8°C

[ 水溶解性 ]:
可溶于：甲醇

3-氨基吡唑MSDS

3-氨基吡唑安全信息

[ 符号 ]:

GHS05, GHS07

[ 信号词 ]:
Danger

[ 危害声明 ]:
H302-H314

[ 警示性声明 ]:
P280-P305 + P351 + P338-P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
C:Corrosive; Xi:Irritant

[ 风险声明 (欧洲) ]:
R22;R34;R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36/37/39-S45

[ 危险品运输编码 ]:
UN 3263 8/PG 2

[ WGK德国 ]:
3

[ 危险类别 ]:
8.0

[ 海关编码 ]:
2933199090

3-氨基吡唑合成路线

3-氨基吡唑上下游产品

3-氨基吡唑上游产品

3-氨基吡唑下游产品

3-氨基吡唑海关

[ 海关编码 ]: 2933199090

[ 中文概述 ]:
2933199090. 其他结构上有非稠合吡唑环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933199090. other compounds containing an unfused pyrazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

3-氨基吡唑文献

Trypanotoxic activity of thiosemicarbazone iron chelators.

Exp. Parasitol. 150 , 7-12, (2015)

Only a few drugs are available for treating sleeping sickness and nagana disease; parasitic infections caused by protozoans of the genus Trypanosoma in sub-Saharan Africa. There is an urgent need for ...

Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.

Cancer Res. 75 , 2863-74, (2015)

Generalized strategies to improve breast cancer treatment remain of interest to develop. In this study, we offer preclinical evidence of an important metabolic mechanism underlying the antitumor activ...

Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

Behav. Brain Res. 291 , 342-50, (2015)

Studies have demonstrated that administration of the neuronal nicotinic receptor agonist varenicline to rats with olivocerebellar lesions attenuates balance deficits on a rotorod and balance beam, but...

更多文献